Edwards Lifesciences (EW) Net Income towards Common Stockholders (2009 - 2025)

Edwards Lifesciences' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $27.0 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 31.3% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at $20.6 million (down 99.25% YoY), while the FY2025 annual figure was $13.4 million, down 99.52% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at $27.0 million, up from -$2.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.7 billion in Q3 2024, with the low at -$7.2 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is $194.7 million (2021), against an average of $314.6 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 5447.75% in 2024, then plunged 540.0% in 2025.
• Edwards Lifesciences' Net Income towards Common Stockholders stood at $335.3 million in 2021, then gained by 18.82% to $398.4 million in 2022, then slumped by 90.81% to $36.6 million in 2023, then increased by 7.38% to $39.3 million in 2024, then tumbled by 31.3% to $27.0 million in 2025.
• Business Quant data shows EW's Net Income towards Common Stockholders at $27.0 million in Q4 2025, -$2.0 million in Q3 2025, and -$4.4 million in Q2 2025.